GeoVax to Highlight Mpox Vaccine Development at Emerging Growth Conference

Biotechnology company GeoVax Labs is set to showcase its Mpox vaccine development at the upcoming Emerging Growth Conference, offering investors and medical professionals a comprehensive update on its vaccine candidate GEO-MVA. The presentation, led by Chairman and CEO David Dodd, will provide critical insights into the company's infectious disease prevention strategies.

During the live, interactive online event, Dodd will focus on the development of GEO-MVA, a vaccine candidate targeting Mpox and smallpox. The presentation represents an important opportunity for stakeholders to understand the potential impact of GeoVax's vaccine research in addressing significant public health challenges.

The conference, scheduled for February 18-19, 2025, will allow real-time interaction between GeoVax's leadership and the investment community. Attendees will have the opportunity to submit questions in advance or during the live event, enabling direct engagement with the company's executive leadership.

This presentation comes at a critical time in infectious disease research, as global health organizations continue to monitor and combat emerging viral threats. GeoVax's work on the Mpox vaccine candidate represents a significant contribution to potential preventative medical solutions for challenging infectious diseases.

The conference presentation will complement GeoVax's broader research portfolio, which includes advanced clinical programs in COVID-19 vaccines and oncology treatments. By highlighting the Mpox vaccine program, the company aims to demonstrate its commitment to developing innovative immunotherapies that address critical global health needs.